HPC
SRNE

HM Payson & Co’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

HM Payson & Co’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-300
Closed -$3K – 1174
2020
Q3 		$3K Sell
300
-700
-70% -$6.41K ﹤0.01% 936
2020
Q2 		$6K Buy
+1,000
New +$3.83K ﹤0.01% 791

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

HM Payson & Co's SRNE Position: Q4 2020 in Review

HM Payson & Co sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2020, closing a stake of 300 shares — an estimated $3K sold.

HM Payson & Co first reported a position in SRNE in Q2 2020 and held it in 2 quarters. The position peaked at $6K in Q2 2020. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

  • HM Payson & Co reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • HM Payson & Co sold 300 Sorrento Therapeutics, Inc. shares in Q4 2020, an estimated $3K.
  • HM Payson & Co first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 2 quarters.
  • HM Payson & Co's Sorrento Therapeutics, Inc. position peaked at $6K in Q2 2020.
  • 219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on HM Payson & Co's 13F filing for Q4 2020, filed 10 Mar 2021.